BioSpace News Archive

CSL Limited announces a reported net profit after tax of $1.90 billion for the 6 months ended 31 December 2023, up 20% on a constant currency basis.

Sensome announced today enrollment of the first patients into a feasibility clinical study using the Clotild ® Smart Guidewire in peripheral artery disease (PAD).

Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has submitted an Orphan Drug Designation (ODD) application to the U.S. Food and Drug Administration (FDA) for crofelemer.

Monogram Orthopaedics Inc. hosted a recorded discussion of features of Monogram’s mBs and mVision technologies with a surgeon panel.

CymaBay Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid.

YS Biopharma Co., Ltd. today issues an official response to the notice of extraordinary meeting of shareholders of YS Biopharma Co., Ltd.

Jaya Biosciences, Inc. reported non-clinical data at the 20th Annual WORLD Symposium ™.

RTW Charitable Foundation announced that it has awarded $900,000 in research grants to support six research studies.

StageBio is pleased to announce the appointment of David Bruning as Chief Executive Officer.

Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder